52周新高排行 | 股票名称 | 收盘价 | 最高价 | 创高率 | | --- | --- | --- | --- | | 景联集团(01751) | 0.510 | 0.840 | 40.00% | | 中国稀土(00769) | 0.680 | 0.690 | 23.21% | | 友谊时光(06820) | 1.180 | 1.180 | 22.92% | | 森浩集团(08285) | 0.035 | 0.038 | 22.58% | | 玮俊生物科技(00660) | 0.169 | 0.199 | 17.06% | | 中国白银集团(00815) | 0.510 | 0.540 | 16.13% | | 金斯瑞生物科技(01548) | 16.980 | 17.140 | 13.66% | | 帝王实业控股(01950) | 0.350 | 0.425 | 13.33% | | 布鲁可(00325) | 193.300 | 198.000 | 13.14% | | 诺诚健华(09969) | 13.160 | 13.720 | 12.64% | | 阿里影业(01060) | 1.060 | 1 ...

行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.3倍，行业中值5.39倍。帝王国际投资 市盈率10.33倍，行业排名第28位；其他大健康国际（02211.HK）为0.56倍、精优药业（00858.HK）为 0.67倍、金斯瑞生物科技（01548.HK）为1.25倍、东瑞制药（02348.HK）为3.03倍、正大企业国际 （03839.HK）为3.21倍。 资料显示，帝王国际投资有限公司是一家在香港上市、专注于肿瘤精准医疗领域的基因检测公司。公司 致力于肿瘤基因检测在临床医学与健康服务中的应用,为临床医生、医院体检、癌症患者、高危健康人 群以及癌症相关领域的研究者提供科学专业的分子诊疗解决方案以及学术研究服务。莲和医疗自主研发 的基因检测产品涵盖呼吸道肿瘤、消化道肿瘤、乳腺及妇科肿瘤、泌尿肿瘤、头颈部肿瘤乃至泛肿瘤 等,贯穿肿瘤诊疗中的早期筛查、辅助诊断、用药指导、预后评估、动态监测等全病程管理环节。广州 莲和医疗是集团在华南片区设立的中心实验室,业务覆盖华南片区,公司类型为有限责任公司(法人独资), 属于盈利性机构。莲和医疗在北京、广州设立医学检验实验室及业务分部,实验室严格按照美国病理学 家协会 ...

4) 自2025年4月24日起暂时停止晏明非执行董事职务，直至截至2025年3月31日止年度的审核工作完成 及董事会另行通知为止。 鉴于：i)公司有义务自2024年12月28日起按每年24%的利率支付总额为人民币5637.78万元的款项，直至 根据呈请悉数支付为止，该款项约占公司截至2024年9月30日总资产的17.8%;ii)呈请可能被证明为无效 的可能性;及iii)呈请已被撤回，董事会认为，截至本公布日期，呈请对公司的运营及财务状况并无重大 不利影响。 另据悉，晏明未经董事会的批准及授权，于2025年1月6日私自成立公司全资附属公司中国帝王，并随后 成立其附属公司(如有)。董事会认为，由于中国帝王的成立并未获得董事会批准，公司将不承认与中国 帝王签署的任何协议的有效性，并将寻求法律意见以否认公司及其他附属公司应承担的任何义务。此 外，董事会将考虑对晏明采取法律行动。如发现涉及违法行为或造成公司损失，董事会会保留对相关人 士追究民事赔偿或刑事责任权利。 2) 透过集团的法律顾问向收货人发送信函以确认i)彼等是否确实收到呈请中提述的货物; ii)彼等是否已 收到销售货物的任何所得款项并要求将所得款项转予公司; ...

4月2日，截至港股收盘，恒生指数下跌0.02%，报23202.53点。帝王国际投资（00928.HK）收报0.029港 元/股，上涨7.41%，成交量220万股，成交额6.32万港元，振幅11.11%。 资料显示，帝王国际投资有限公司是一家在香港上市、专注于肿瘤精准医疗领域的基因检测公司。公司 致力于肿瘤基因检测在临床医学与健康服务中的应用,为临床医生、医院体检、癌症患者、高危健康人 群以及癌症相关领域的研究者提供科学专业的分子诊疗解决方案以及学术研究服务。莲和医疗自主研发 的基因检测产品涵盖呼吸道肿瘤、消化道肿瘤、乳腺及妇科肿瘤、泌尿肿瘤、头颈部肿瘤乃至泛肿瘤 等,贯穿肿瘤诊疗中的早期筛查、辅助诊断、用药指导、预后评估、动态监测等全病程管理环节。广州 莲和医疗是集团在华南片区设立的中心实验室,业务覆盖华南片区,公司类型为有限责任公司(法人独资), 属于盈利性机构。莲和医疗在北京、广州设立医学检验实验室及业务分部,实验室严格按照美国病理学 家协会(CAP)和ISO15189-2012标准建立完善的质量管理体系,连续3年以全部满分成绩通过卫生部临床检 验中心(NCCL高通量测序室间质评,并在欧洲分子基因诊断质量 ...

Financial Performance - For the six months ended 30 September 2024, the Group reported a revenue of HK$37,186,000, a decrease of 55.5% compared to HK$83,427,000 in the same period of 2023[18] - The Group's profit before taxation for the six months ended 30 September 2024 was a loss of HK$2,690,000, compared to a profit of HK$963,000 in the same period of 2023[39] - Gross profit for the same period was HK$1,009,000, down from HK$12,022,000, reflecting a significant decline in profitability[51] - The operating loss for the period was HK$1,553,000, compared to an operating profit of HK$2,690,000 in the previous year[51] - The loss attributable to owners of the Company for the period was HK$1,587,000, contrasting with a profit of HK$1,693,000 in the same period last year[51] - The Group's loss for the six months ended 30 September 2024 was approximately HK$1.59 million, compared to a profit of HK$0.96 million in the same period last year[185] Cost Management - The cost of inventories recognized as expenses was HK$36,177,000, down 49.3% from HK$71,405,000 in the previous year[21] - Employee benefit expenses, including directors' remuneration, totaled HK$230,000, a significant decrease of 94.6% from HK$4,284,000 in 2023[21] - The Group's total finance costs for the period included interest on lease liabilities amounting to HK$75,000, down from HK$92,000 in the previous year[21] - Selling and distribution costs and administrative expenses totaled HK$2,487,000, compared to HK$9,243,000 in the previous year, indicating a reduction in operational expenses[51] - The Group aims to enhance profitability by tightening cost controls over operating expenses[88] Cash Flow and Liquidity - For the six months ended September 30, 2024, the net cash generated from operating activities was HK$77,000, compared to a net cash used of HK$17,058,000 in the same period last year[82] - The company reported a net decrease in cash and cash equivalents of HK$416,000 during the period[82] - The Group had current liabilities of approximately HK$68,840,000, while cash and cash equivalents were only about HK$179,000[88] - The net cash outflow for the six months ended 30 September 2024 was approximately HK$416,000[86] - The Group is implementing measures to speed up the collection of outstanding trade receivables to improve cash flow[88] Segment Performance - Segment profit for healthcare products and services was HK$391,000, while the liquor sales segment reported a profit of HK$11,496,000 for the six months ended 30 September 2023[39] - The healthcare products and services business segment did not generate any revenue during the review period due to resource allocation for new business initiatives[185] - The healthcare segment recorded no sales, compared to HK$41.27 million for the same period in 2023, resulting in a segment loss of HK$0.08 million[186] - The loss was primarily attributable to the liquor segment and healthcare products and services business, which recorded losses of approximately HK$0.41 million and HK$0.08 million, respectively[185] Shareholder Actions - The new share option scheme approved by shareholders at the 2022 AGM is valid for ten years starting from 12 October 2022[4] - The company successfully placed 160,480,000 shares at a price of HK$0.06 per share, raising gross proceeds of approximately HK$9,629,000[156] - The company also completed a subscription of 147,920,000 shares at HK$0.065 per share, generating gross proceeds of approximately HK$9,615,000[156] - The issued and fully paid ordinary shares increased to 1,850,425,000 shares with a total value of HK$92,521,000 as of 30 September 2024[172] Future Outlook - The company is focusing on restructuring and cost management strategies to improve financial performance in the upcoming periods[51] - Future outlook includes potential market expansion and new product development initiatives to drive revenue growth[51] - The liquor market, particularly for Maotai-flavor liquor, is expected to have broad prospects, with the "Diwangchi" brand anticipated to become a mainstream brand due to its quality and packaging[188] Financial Position - Total equity as of September 30, 2024, was HK$265,701,000, a slight decrease from HK$266,049,000 as of the previous year[56] - Current assets totaled HK$331,647,000, with inventories at HK$162,143,000 and trade and other receivables at HK$169,325,000[73] - The company's net assets as of September 30, 2024, were HK$265,701,000, a slight decrease from HK$266,049,000 as of March 31, 2024[73] - Total liabilities decreased from HK$67,652,000 to HK$68,840,000, with current liabilities including trade and other payables at HK$43,328,000[73] Taxation - Current tax for the PRC Enterprise Income Tax was HK$35,000, a decrease from HK$1,724,000 in the previous year[37] - The Hong Kong Profits Tax is calculated under a two-tier system, with the first HK$2 million taxed at 8.25% and the remaining at 16.5%[115] - The Group is not subject to income tax in the Cayman Islands and British Virgin Islands for both interim periods[114] Compliance and Risk Management - The company has implemented financial risk management policies to ensure payables are settled within the credit timeframe of 90 days[140] - The Group's financial position indicates significant uncertainty regarding its ability to continue as a going concern[86] - The company is facing competitive challenges in the money lending business, with demanding compliance work[186]

Financial Performance - For the six months ended September 30, 2024, the company reported revenue of HKD 37,186,000, a decrease of 55.5% compared to HKD 83,427,000 in the same period of 2023[2] - The gross profit for the same period was HKD 1,009,000, down from HKD 12,022,000, indicating a significant decline in profitability[2] - The company incurred an operating loss of HKD 1,553,000, compared to an operating profit of HKD 2,690,000 in the previous year[4] - The net loss attributable to the company’s owners for the period was HKD 1,587,000, a reversal from a profit of HKD 1,693,000 in 2023[4] - The basic and diluted loss per share for the period was HKD 0.09, compared to earnings of HKD 0.11 per share in the same period last year[4] - The overall gross profit margin for the company was 2.71%, down from 14.41% in the previous year[46] - The company recorded a loss of approximately HKD 1,590,000 for the six months ended September 30, 2024, compared to a profit of HKD 960,000 for the same period in 2023[47] - Total loss before tax for the group was HKD (1,553,000), with a net loss of HKD (1,588,000) for the six months ended September 30, 2024[17] Assets and Liabilities - The total assets as of September 30, 2024, were HKD 331,647,000, slightly up from HKD 330,707,000 as of March 31, 2024[6] - Current liabilities amounted to HKD 68,840,000, with cash and cash equivalents at approximately HKD 179,000, indicating potential liquidity issues[11] - The company had trade payables of HKD 28,775,000 as of September 30, 2024, slightly up from HKD 28,380,000 as of March 31, 2024[37] - Trade receivables amounted to HKD 96,230,000 as of September 30, 2024, an increase from HKD 73,560,000 as of March 31, 2024[34] - The company’s equity attributable to owners was HKD 269,500,000, a slight decrease from HKD 269,847,000 as of March 31, 2024[6] - The capital debt ratio as of September 30, 2024, was approximately 0.94%, unchanged from March 31, 2024[56] Revenue Segmentation - The group reported a total revenue of HKD 37,186,000 for the health products and services business, with a segment loss of HKD (80,000) for the six months ended September 30, 2024[17] - The liquor sales business generated revenue of HKD 37,186,000, resulting in a segment loss of HKD (410,000) for the same period[17] - The health products and services segment did not generate any revenue during the reporting period, compared to HKD 41,270,000 in the previous year, resulting in a segment loss of HKD 80,000[48] - The liquor sales segment generated revenue of HKD 37,190,000 for the six months ending September 30, 2024, with a segment loss of HKD 410,000[51] - The group’s revenue from external customers in China was HKD 37,186,000, down from HKD 42,125,000 in the previous period[19] Cash Flow and Financing - The company has taken measures to accelerate the collection of outstanding trade receivables to improve cash flow[11] - The group has implemented cost control measures to enhance profitability and improve future cash flow[12] - The group plans to actively seek new financing arrangements to meet operational and financial needs[12] - The group had cash and bank balances of approximately HKD 200,000 as of September 30, 2024, down from approximately HKD 500,000 as of March 31, 2024[56] Corporate Governance - The board consists of four executive directors and four independent non-executive directors, and the financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards[54] - The board of directors includes Chairman and CEO Wang Mengyao, and other executive and independent non-executive directors[73] Other Information - The group did not declare any dividends for the current interim period[30] - The company did not recommend an interim dividend for the six months ending September 30, 2024, consistent with the previous year[67] - The group has not engaged in any significant acquisitions or disposals of subsidiaries or associates during the reporting period[61] - The company has not pledged any assets as of September 30, 2024[62] - The group has no significant contingent liabilities as of September 30, 2024[63] - The company allowed credit terms ranging from 0 to 365 days for health products and services and liquor sales[34] - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from April 1, 2024, with no significant impact on accounting policies or financial statements[13] - The lending business recorded no revenue for the six months ending September 30, 2024, compared to HKD 30,000 for the same period last year, maintaining a gross profit margin of 100% due to no financial costs[50] - The company has exclusive rights to sell "Emperor Pool" liquor in China, which is expected to enhance financial performance and profitability due to the growing demand for liquor driven by rising living standards[51] - The announcement date is November 29, 2024, indicating a recent financial update[73]

Corporate Governance - As of March 31, 2024, the Board consists of 11 Directors, with 2 female Directors, achieving a gender diversity representation of approximately 18.2%[9] - The Company has not set any specific objectives for gender ratio in workforce or senior management, focusing on merit-based appointments[9] - The Nomination Committee identifies candidates for directorship from various channels, including internal promotions and management referrals[9] - The Group strictly adheres to relevant regulations and laws, with no significant cases of non-compliance related to bribery, extortion, fraud, or money laundering reported for the year ended March 31, 2024[37] - The Company has adopted a whistleblowing policy to encourage employees to report serious concerns regarding financial reporting and compliance without fear of reprisal[37] - The Audit Committee held 3 meetings during the year ended March 31, 2024, to oversee the Group's control systems[14] - The Board is responsible for defining management structure and determining the nature and extent of significant risks[23] - The Company is committed to full compliance with disclosure obligations under the Listing Rules and applicable laws, ensuring equal access to information for all shareholders[40] - The Group emphasizes fairness and honesty in business dealings, with strict policies against corruption and fraudulent activities[37] Financial Performance - For the year ended March 31, 2024, the profit attributable to owners of the Company was HK$15,818,000, a significant recovery from a loss of HK$25,192,000 in the previous year[113] - Total comprehensive income for the year attributable to owners of the Company was HK$13,498,000, compared to a loss of HK$51,143,000 in 2023[113] - Revenue for 2024 reached HK$233,681,000, an increase of 4.0% compared to HK$223,853,000 in 2023[154] - Gross profit for the year was HK$37,789,000, significantly up from HK$12,049,000 in the previous year[154] - Profit before tax improved to HK$23,870,000 from a loss of HK$30,709,000 in 2023[154] - Profit for the year was HK$15,114,000, recovering from a loss of HK$31,753,000 in 2023[154] - Other income and gains increased to HK$6,450,000 from HK$1,743,000 in the previous year[154] - Administrative and other expenses decreased to HK$18,819,000 from HK$43,320,000, reflecting a reduction of 56.6%[154] - Total comprehensive income for the year was HK$11,908,000, recovering from a total comprehensive loss of HK$56,754,000 in 2023[154] Cash Flow and Liquidity - The Group reported a net operating cash outflow of approximately HK$32,319,000 for the year ended March 31, 2024[83] - Current liabilities amounted to approximately HK$67,652,000, while cash and cash equivalents were only approximately HK$473,000[124] - The Group's net current assets increased to HK$263,055,000 from HK$215,456,000 in 2023, indicating improved liquidity[115] Investments and Assets - The Company disposed of an equity investment at fair value through other comprehensive income during the year ended 31 March 2023[79] - Non-current assets increased to HK$138,000,000 from HK$17,750,000 in 2023, indicating significant investment in property, plant, and equipment[115] - The total equity attributable to owners of the Company rose to HK$269,847,000 from HK$237,505,000 in the previous year[117] - The Company had inventories valued at HK$196,605,000 as of March 31, 2024, reflecting a strategic buildup of stock[115] - Trade and other receivables totaled approximately HK$133,629,000 as of March 31, 2024, which is material to the consolidated financial statements[124] Audit and Compliance - The internal audit function was appointed to review risk management and internal control systems, with findings and recommendations for improvement identified[67] - The Board confirmed the effectiveness of the Control Systems for the year ended 31 March 2024, with annual reviews conducted by the Audit Committee[67] - The audit report indicates that reasonable assurance was obtained regarding the absence of material misstatements in the consolidated financial statements[133] - The auditor's report indicated a qualified opinion, highlighting potential effects of certain matters on the financial statements[200] Business Development - The company has started engaging in liquor sales to capitalize on the growing demand for wine in China, which is expected to generate stable cash flows and diversify income streams[172] - In September 2023, the company obtained an exclusive sub-licence to use the "Diwangchi" liquor brand in China and commenced sales of Maotai-flavor liquor under this brand[172] - The Maotai-flavor liquor under the "Diwangchi" brand is anticipated to become one of the mainstream brands in the market due to its excellent quality and innovative marketing[172] - The liquor market in China is experiencing continued prosperity, and the Maotai-flavor liquor market has broad prospects for growth[172] - The Group aims to create value and higher returns for shareholders through active exploration of new business opportunities, including the liquor segment[198] Genetic Testing and Health Products - The Group continues to expand its genetic testing services both in Hong Kong and overseas, responding to increased demand for health products post-COVID-19[184] - The Group is committed to developing health data analysis products and innovative medical technology products to enhance its service offerings[184]

Financial Position - The company has a current liability of approximately HKD 67,652,000, but only has cash and cash equivalents of about HKD 473,000[33]. - The asset-liability ratio as of March 31, 2024, is approximately 0.94%, compared to 1.07% as of March 31, 2023[24]. - Total assets as of March 31, 2024, amounted to 336,134,000 HKD, while total liabilities were 70,085,000 HKD[66]. - The company’s total equity increased to HKD 266,049,000 from HKD 232,995,000, showing a strengthening of the financial position[52]. - The group’s total liabilities for trade and other payables increased to HKD 41,900,000 as of March 31, 2024, from HKD 19,626,000 as of March 31, 2023[126]. - There are no significant contingent liabilities reported for the company as of March 31, 2024, and March 31, 2023[188]. Cash Flow and Liquidity - The company reported a net operating cash outflow of approximately HKD 32,319,000 for the year ended March 31, 2024, indicating significant uncertainty regarding its ability to continue as a going concern[33]. - The company reported a net cash outflow from operations of approximately 32,319,000 HKD for the fiscal year ending March 31, 2024[77]. - The company has current liabilities of approximately 67,652,000 HKD, with cash and cash equivalents of only about 473,000 HKD, indicating significant liquidity concerns[77]. - The company has initiated a new alcoholic beverage sales business, anticipating it will generate stable cash flow and diversify revenue streams[136]. - The group’s cash flow from operations is expected to improve due to the new alcoholic beverage segment, which is projected to enhance financial performance and profitability[136]. Revenue and Profitability - For the fiscal year ending March 31, 2024, the company reported total revenue of HKD 233,681,000, an increase of 4.1% from HKD 223,853,000 in the previous year[57]. - The gross profit for the year was HKD 37,789,000, compared to HKD 12,049,000 in the previous year, indicating a significant improvement[51]. - The net profit attributable to the owners of the company was HKD 15,818,000, recovering from a loss of HKD 25,192,000 in the previous year[43]. - The company recorded a total comprehensive income of HKD 11,908,000, a substantial recovery from a loss of HKD 56,754,000 in the previous year[50]. - The company reported a profit before tax of HKD 23,870,000 for the year, compared to a loss of HKD 30,709,000 for the previous year[88]. - The liquor sales division generated a profit of HKD 28,040,000, indicating strong performance in this segment[109]. - The company plans to strengthen cost control measures to improve profitability and operational cash flow in the future[78]. Business Operations - The company has made a full impairment of its investment in the joint venture Manrui Bio for the year ended March 31, 2022[10]. - The company has exclusive licensing rights for the "Emperor Pool" liquor brand in China, which commenced sales in September 2023[112]. - The company has reduced its workforce to 13 full-time employees and 0 part-time employees as of March 31, 2024, down from 13 full-time and 1 part-time employee the previous year[19]. - The company plans to continue focusing on its health products and liquor sales, which have shown promising revenue growth[57]. - The company is actively exploring new business opportunities to create value and deliver higher returns to shareholders[136]. Investments and Prepayments - The company made a prepayment of HKD 28,889,000 to Supplier A for disinfectant products, which was later canceled, and a refund of approximately HKD 23,333,000 was received[143]. - The company prepaid HKD 69,565,000 to Supplier B for disinfectant products after canceling the agreement with Supplier A[150]. - The company made a prepayment of approximately HKD 8,081,000 to Supplier C for vehicle modification services, which has not been provided as planned[144]. - The company sold its subsidiary related to vehicle modification services, recording a gain of approximately HKD 2,116,000[152]. - The company invested RMB 30,000,000 (approximately HKD 36,990,000) and RMB 25,000,000 (approximately HKD 30,824,000) in two joint ventures, holding 25% equity in each[141]. Compliance and Governance - The company has maintained compliance with the corporate governance code as per the Hong Kong Stock Exchange Listing Rules as of March 31, 2024[21]. - The company will continue to review and take appropriate measures to comply with corporate governance codes[191]. - The audit committee has agreed on the handling of prepayments made to Suppliers B and C[182][183]. Shareholder Returns - The company did not recommend any dividend payments for the year ended March 31, 2024[97]. - The board does not recommend the payment of a final dividend for the year ending March 31, 2024, consistent with the previous year[185]. - Basic and diluted earnings per share for the year ended March 31, 2024, were approximately HKD 0.96, compared to a loss of HKD 1.71 per share for the year ended March 31, 2023[165].

Financial Performance - Revenue for the six months ended September 30, 2023, increased to HK$83,427,000, up 48% from HK$56,407,000 in the same period of 2022[10] - Gross profit for the period was HK$12,022,000, representing a gross margin of approximately 14.4%, compared to HK$5,055,000 in 2022[10] - Operating profit for the period was HK$2,690,000, a significant improvement from an operating loss of HK$1,341,000 in the previous year[10] - Profit attributable to owners of the Company was HK$1,693,000, compared to a loss of HK$1,262,000 in the same period last year[10] - The Group reported a profit before taxation of HK$2,690,000 and a profit for the period of HK$963,000 after accounting for income tax of HK$1,727,000[41] - The Group's profit for the six months ended September 30, 2023, was approximately HK$0.96 million, compared to a loss of HK$1.34 million in the same period last year[110] Comprehensive Income and Expenses - Total comprehensive expense for the period was HK$727,000, a substantial reduction from HK$27,732,000 in 2022[13] - The company reported a total comprehensive expense of HK$1,690,000 for the period ended September 30, 2023, compared to a total comprehensive income of HK$3,000 in the previous period[23] Assets and Liabilities - Non-current assets decreased to HK$16,989,000 as of September 30, 2023, down from HK$20,001,000 as of March 31, 2023[14] - Current assets increased to HK$273,681,000, compared to HK$244,268,000 at the end of the previous fiscal year[14] - Net assets as of September 30, 2023, were HK$233,605,000, slightly up from HK$232,995,000 as of March 31, 2023[14] - Total equity as of September 30, 2023, is HK$233,605,000, an increase from HK$232,995,000 as of March 31, 2023, reflecting a growth of 0.27%[17] - The accumulated losses as of September 30, 2023, are HK$1,313,797,000, slightly improved from HK$1,315,490,000 as of April 1, 2023[18] Cash Flow - Net cash used in operating activities for the six months ended September 30, 2023, is HK$17,058,000, an improvement from HK$41,300,000 in the same period of 2022[23] - Cash and cash equivalents at the end of the period on September 30, 2023, decreased to HK$301,000 from HK$112,152,000 at the end of the previous period[23] Segment Performance - For the six months ended September 30, 2023, the Group's total turnover was HK$83,427,000, with external sales from healthcare products and services at HK$41,265,000, money lending at HK$31,000, and liquor sales at HK$42,131,000[41] - The segment profit for healthcare products and services was HK$391,000, while the money lending segment reported a loss of HK$94,000, and the liquor sales segment generated a profit of HK$11,496,000, resulting in a total segment profit of HK$11,793,000[41] - The healthcare products and services segment showed a decrease in turnover compared to the previous period, indicating potential market challenges or shifts in consumer demand[45] - Revenue from the healthcare products and services business dropped by approximately 26.8% to HK$41.27 million compared to the same period last year[111] Market and Revenue Insights - Revenue from external customers for the six months ended 30 September 2023 was HK$83,427,000, a 48% increase from HK$56,407,000 in the same period of 2022[48] - Revenue from the PRC market increased to HK$42,125,000 in 2023 from HK$29,366,000 in 2022, representing a 43% growth[48] - Revenue from Hong Kong also saw a significant rise, reaching HK$41,302,000 in 2023 compared to HK$27,041,000 in 2022, marking a 53% increase[48] Shareholder Information - The company changed its English name from "Life Healthcare Group Limited" to "King International Investment Limited" and its Chinese name accordingly[167] - The company did not declare or propose any dividends during both interim periods[62] - The Group's total borrowings remained at HK$2,500,000 as of September 30, 2023, consistent with the amount as of March 31, 2023[139] Share Options and Management - The company adopted a share option scheme valid for ten years starting from September 18, 2012, allowing eligible participants to acquire interests in the company[178] - As of September 30, 2023, there were 86,040,000 share options outstanding under the Share Option Scheme, with no options exercised during the six-month period[182] - The company has undergone changes in its board of directors, including the appointment of new executive directors and the resignation of others in August 2023[187] Future Outlook - The Group's financial performance is expected to improve with the diversification into the liquor business, which is anticipated to generate stable cash flows[124] - The Maotai-flavor liquor under the "Diwangchi" brand is expected to become a mainstream brand in the market due to its quality and innovative marketing strategies[126]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 截至二零二三年九月三十日止六個月 中期業績公佈 中期業績 蓮和醫療健康集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈， 本公司及其附屬公司（統稱「本集團」）截至二零二三年九月三十日止六個月之未 經審核簡明綜合業績連同二零二二年同期之比較數字（經本公司審核委員會（「審 核委員會」）審閱及同意）如下： 簡明綜合損益及其他全面收益表 截至二零二三年九月三十日止六個月 未經審核 截至九月三十日止六個月 二零二三年 二零二二年 附註 千港元 千港元 ...